Clinical Trial

A Study of CM336 in Patients With Relapsed or Refractory Multiple Myeloma

Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
This is a multi-center, open-label, Phase 1/2 study in China to evaluate the safety, tolerability, efficacy, pharmacokinetics, pharmacodynamics and immunogenicity of CM336 in patients with relapsed or refractory multiple myeloma. This study consists of a dose escalation part (Phase 1) and a dose extension part (Phase 2 ). The safety and tolerability of CM336 will be evaluated in Phase 1 study, as well as the maximum tolerated dose (MTD) and the recommended dose level for Phase 2 study will be determined. The efficacy of CM336 will be evaluated in Phase 2 study.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2022-03-18.
Status change: Not Yet Recruiting → Recruiting 2024-10-14
Trial Details
NCT Number NCT05299424
Lead Sponsor Keymed Biosciences Co.Ltd
Conditions Multiple Myeloma
Enrollment 48 participants
Start Date 2022-08-09
Primary Completion 2026-12 (estimated)
Study Completion 2026-12 (estimated)
Updated on ClinicalTrials.gov 2024-10-15